ReportGem ReportGem EN

普通外文研报

In Case You Missed It: Weekly Equity Market Commentary & Conviction Calls

发布日期: 2026-06-18研究机构: Barclays报告页数: 9原文语言: 英语证据页码: 1

研报英文原文证据摘录

In Case You Missed It: Weekly Equity Market Commentary & Conviction Calls

Equity Research

Equity PMG

18 June 2026

In Case You Missed It

Weekly Equity Market

Commentary & Conviction Calls

While the US-Iran deal announcement was a positive for

U.S. Equity Product Management

equities in the holiday-shortened week, Wednesday's FOMC Group

meeting tempered the enthusiasm slightly given the hawkish Terence Malone* + 1 212 526 7578

turn under Chair Warsh, leading to increased expectations of terence.malone@barclays.com

a potential rate hike this year. BCI, US

Andrew Ferremi*

+1 212 526 8257

andrew.ferremi@barclays.com

Research Conviction Calls BCI, US

Hims & Hers Health: Our Proprietary Data Points to Sharp Inflection; Reit OW PT to

$39 (06/17/2026). Glen Santangelo notes that early traction from the Novo partnership has been

robust, with >125,000 Wegovy shipments fulfilled within six weeks of introduction, strong

conversion to branded therapy, and high engagement, reflecting patient willingness to pay for

clinically validated, safe, and effective therapies. Moreover, his alternative data has started to

show improvement in the time since the partnership was announced on March 9. There has

been a positive inflection in April (+12% y/y) followed by even stronger traffic in May (+35% y/y).

As for his proprietary Barclaycard data, the number of transactions is improving on a sequential

basis, and total spend is up – which he believes is partially a function of the switch from multi-

month subscriptions to a single-month model for the branded GLP-1s. In addition, he expects

growth broadening beyond weight loss, as he sees testosterone, easing sexual health

headwinds, and international expansion all playing a role with peptides as the next catalyst.

本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。

打开研报阅读器